Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bone marrow + eptotermin alfa
- Development stage
- Discontinued
- Lead developer
- Stryker
- Modality
- Cell Therapies, Recombinant Proteins and Enzymes
- Administration
- Percutaneous
01
Overview
Bone marrow + eptotermin alfa is an investigational combination therapy consisting of autologous unconcentrated bone marrow and recombinant bone morphogenetic protein 7 (BMP7, also known as eptotermin alfa or OP-1). Developed by the University Hospital of Lille (CHU de Lille), this treatment was designed as an adjunct to core decompression (surgical drilling) for patients with Ficat stage I-III osteonecrosis (avascular necrosis) of the femoral head. The autologous bone marrow serves as a source of osteogenic stem cells, while BMP7, a member of the TGF-beta superfamily, acts as a potent inducer of bone formation by stimulating the differentiation of mesenchymal cells into osteoblasts. The clinical development of this combination was terminated following the discontinuation of BMP7's commercial availability by its manufacturer, Stryker.
- Brand names
- OP-1OP1OP 1
- Other names
- bone marrow + BMP7bone marrow + bone morphogenetic protein 7bone marrow + OP-1bone marrow + Osteogenic Protein-1autologous bone marrow + recombinant BMP7
02
Targets
ACVR1 (Activin receptor type I)ACVR2A (Activin receptor type 2A)ACVR2B (Activin receptor type IIB)BMPR1ABMPR1BBMPR2 (Bone morphogenetic protein receptor type II)
Beyond the preview
Go deeper on bone marrow + eptotermin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bone marrow + eptotermin alfa.